This trial has already reached total recruitment with 900 patients, and outcomes are awaited. Also, combinations of other pazopanib regimens with other chemotherapy regimens could still be possible and therefore are at the moment staying examined in clinical studies . ACKNOWLEDGEMENTS Fiscal assistance for health care editorial assistance was presented by GlaxoSmithKline. We thank the individuals and their households and all investigators who participated in this trial. TNF-Alpha Signaling Pathway We acknowledge Jerome F Sah, PhD, ProEd Communications, Inc., for his health-related editorial support with this particular manuscript. Conflict of Interest Andreas du Bois obtained honoraria for educational activities from GSK, Roche, PharmaMar, Schering Plough, Novartis, and Astra Zeneca. Furthermore, Andreas du Bois has participated in advisory boards and has received monetary compensation from Astra Zeneca, Roche, PharmaMar, Johnson & Johnson, Schering Plough, and Amgen. Ignace Vergote has been a consultant, received travel funding, and/or received grants from Algeta, Amgen NV, AstraZeneca, Boehringer-Ingelheim, Bristol- Myers Squibb, Eli Lilly, Fresenius, GE Healthcare, GlaxoSmith- Kline, Janssen-Cilag, Menarini Ricerche, Merck Sharp & Dohme, Morphotek, Nektar Therapeutics, Novo Nordisk Pharmaceutical Industries, Oasmia Pharmaceutical, PharmaMar, Hoffmann- LaRoche, Sanofi-Aventis, Schering-Plough, Sigma Tau Pharmaceuticals, and Telik.
Pauline Wimberger received honoraria for educational activities from GlaxoSmithKline, Roche, PharmaMar, and Schering-Plough.
Isabelle Ray-Coquard obtained honoraria for educational activities enzalutamide CYP17 Inhibitors from Roche, PharmaMar, Schering-Plough, Novartis, and Astra Zeneca. On top of that, Isabelle Ray-Coquard has participated in advisory boards and has received monetary compensation from Roche, PharmaMar, Johnson & Johnson, Schering-Plough, and Abbott. Laurie Baylor Curtis and Ionel Mitrica are employed by GlaxoSmithKline. Philipp Harter declare no conflict of interest. As a result of the introduction of targeted anticancer therapy for advanced renal cell carcinoma and metastatic RCC , the overall survival time of individuals with this disease has increased dramatically. At the moment, six U.S. Food and Drug Administration and European Medicines Agency approved targeted agents are available for treating RCC: sunitinib malate , sorafenib tosylate , pazopanib , temsirolimus , everolimus , and bevacizumab plus interferon-_2a. These agents are indicated as first- and second-line therapies. Bevacizumab differs from the other agents reported here in that it blocks vascular endothelial growth factor, whereas the other agents block multiple receptors and intracellular pathways . With longer survival times, it has become even more important to optimize health-related quality of life during treatment.